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Abstract
Purpose of Review To describe the recent advances in the field towards the prevention and early recognition of Psoriatic Arthritis
(PsA).
Recent Findings Defining the preclinical phase of PsA remains challenging since up to 50% of subjects with psoriasis have
subclinical imaging enthesopathy, but many of these do not progress to PsA. Nevertheless, there is evidence that subjects with
subclinical imaging enthesopathy are at increased risk of developing PsA. In recent years, it has been shown that both PsA and
anti-citrullinated protein antibodies (ACPA) positive rheumatoid arthritis (RA) are characterized by a subclinical phase of non-
specific or brief duration arthralgia with shared imaging features accounting for joint symptomatology. Sonographically deter-
mined tenosynovitis and enthesitis are the key imaging features present in non-specific PsO arthralgia that are at risk of future
PsA development. Furthermore, the early phases of PsA are complicated by factors including body mass index (BMI), which is a
risk factor for PsA, but BMI is also associated with imaging abnormalities on enthesopathy. Fully disentangling these clinical and
imaging factors will be important for enrichment for imminent PsA so that disease prevention strategies can be investigated.
Summary Psoriasis patients with arthralgia have a higher prevalence of tenosynovitis and imaging enthesopathy is at higher risk
of transitioning to overt PsA.
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Introduction
Anti-citrullinated protein antibodies (ACPA) positive patients
and subjects with psoriasis are two populations at higher risk
of respectively developing rheumatoid arthritis (RA) and pso-
riatic arthritis (PsA) [1, 2]. However, unlike preclinical RA
where therapy may be potentially toxic in an otherwise
asymptomatic patient, the presence of psoriasis, that is often
extensive sets up a scenario whereby dermatological directed
therapy could prevent arthritis evolution at “no extra cost”.
There is a strong link between subclinical enthesopathy and
psoriasis, but how this translates into frank PsA development
remains uncertain [3, 4]. Nail disease in PsA is a strong pre-
dictor of future PsA development, and it has been shown that
the nail is anchored to the skeleton and that subclinical imag-
ing enthesopathy is common in psoriasis subjects with nail
disease but without psoriasis [5, 6]. In animal models of
PsA, the earliest lesion is at the enthesis [7, 8]. Collectively
these findings indicate that imaging of the joints in psoriasis
and especially enthesopathy may be relevant for predicting
PsA development and hence facilitate timely intervention. In
this review, we discuss the role of imaging as possible bio-
marker of PsA development and as a tool to better understand
the mechanisms of transition from psoriasis to PsA.
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The Transition to Psoriatic Arthritis
PsAmostly develops in patients with an established diagnosis of
psoriasis, the diagnosis of psoriasis occurring after the onset of
arthritis only in 15% of PsA cases [9]. The incidence of PsA after
the onset of psoriasis increases with time, reaching to 20% after
30 years [10]. It is important to identify patients at risk of devel-
oping PsA which can enable targeting prevention. Nail, scalp,
and inverse psoriasis and the severity of the cutaneous disease are
the clinical features with higher risk of PsA development [5, 9].
Among comorbidities, obesity is associated with PsA develop-
ment [11, 12]. There is also a link between the magnitude of
body mass index (BMI) elevation and future PsA risk [12].
From a genetic point of view, as for RA, a first degree relative
with arthritis could contribute to increase this risk [13]. Eder et al.
highlighted that arthralgia in psoriasis females is a strong predic-
tor of PsA development [14••]. We recently confirmed these
results in a longitudinal study in which psoriatic patients with
arthralgia (PsOAr) weremore prone to develop PsA compared to
psoriatic patients without musculoskeletal complaints (PsO)
[15••]. These studies bring attention to symptoms referred by
patients in their preclinical phases of PsA as possible markers
of imminent PsA development.
It has recently been proposed that there are three clinically
quiet stages after psoriasis onset and before clinically detected
PsA [16••]. These are as follows: (a) preclinical phase which is
characterized by aberrant activation of the immune systemwhich
may originate from the skin, intestinal mucosa or the entheses.
(b) Subclinical PsA phase with soluble biomarkers and imaging
findings with no clinical symptoms. (c) Prodromal PsA in which
patients have arthralgia and fatigue with no synovitis and or
enthesitis on physical exam yet (Illustration 1). In our opinion,
when PsA develops after acute joint injury or after infection, this
model could not be necessarily applied. In this article we sum-
marize the literature on imaging in psoriasis and PsA and point
out how the prodromal phase of PsA actually is associated with
tenosynovitis on imaging.We also discuss the possibility of PsA
prevention based on the emerging imaging data.
Subclinical PsA
Imaging Features in Psoriasis Patients
without Musculoskeletal Complaints
High-frequency sonography is an imaging technique to evaluate
skin, nail, joints, and entheses in psoriatic patients that can allow
detection of subclinical signs of PsA (Fig. 1).Many studies had
compared the ultrasound findings of the large entheses (mostly
the weight bearing lower limb entheses) in PsO patients and
healthy controls (HCs), and the majority of them showed PsO
patients had more entheseal inflammation on ultrasonography
(US), despite being asymptomatic [17]. Simon et al. showed that
the number of enthesophytes detected by high-resolution periph-
eral quantitative computed tomography (HR-pQCT) was signif-
icantly greater compared to HCs [18]. Furthermore, they found
that duration of skin disease influenced enthesophytes burden in
PsO [18]. Recently, also subclinical synovitis was found signif-
icantly more frequent in PsO than in HCs [19, 20]. Currently, if
the imaging criteria of subclinical inflammation are used, up to
half of PsO patients could be classified as subclinical PsA [20]
(Illustration 1). The identification of specific imaging lesions,
associated with overt clinical PsA development, will be the chal-
lenge for the coming years, and this step will be essential to
stratify correctly PsO patients at risk for PsA development [4,
6]. Subclinical inflammation in PsO patient should be assessed
not only at enthesis and synovial level but also in the vessels
allowing to prevent cardiovascular events. Metabolic imaging
studies, such 18F-fluorodeoxyglucose positron emission
tomography-computed tomography (18F-FDG PET/TC), have
documented capability to assess vascular disease and the ability
of anti-TNF therapy to reduce vascular uptake after a year of
therapy [21]. Few studies were designed to study the increased
cardiovascular risk in PsO using magnetic resonance imaging
(MRI) to assess aortic wall thickness or using US to assess ca-
rotid intima-media thickness [22, 23].
Non-Specific Joint Pain in Psoriasis or Prodromal PsA
Imaging Features in Psoriasis Patients with Arthralgia
The last transition phase from psoriasis to PsA, named prodro-
mal PsA, seems to be clinically characterized by non-specific
musculoskeletal symptoms [14••, 16••] (Illustration 1). The
high risk and the likely short time before progression to clini-
cally evident PsA give the opportunity to visualize the possible
mechanisms of expansion of inflammation from the skin to
joints or the evolution from a subclinical form to a clinically
manifested disease. In a clinical and sonographic study on
PsOAr, sonographically determined tenosynovitis was the most
significant contributor to symptoms in PsOAr; indeed, sono-
graphic investigation revealed tenosynovitis, mainly of the flex-
or tendon of the hands, in 29.5% PsOAr patients compared to
5.3% in PsO patients [15••] (Fig. 2). Active enthesitis and sy-
novitis, albeit commoner in PsOAr, did not reach a significant
difference between PsOAr and PsO cohorts but in the longitu-
dinal part, sonographically determined enthesitis was the only
US feature linked to the future evolution of PsA [15] (Fig. 1).
This finding replicated the original longitudinal analysis show-
ing that baseline enthesopathy predicted PsA [3]. Faustini et al.
confirmed this relationship between subclinical inflammation
detected and PsA, highlighting that patients with hands synovi-
tis detected by MRI and arthralgia had 55.5% likelihood to
develop PSA within 1 year [24]. Temporally close to clinical
PsA diagnosis, psoriatic inflammatory arthralgia could be con-
sidered as an intermediate between PsOAr and very early early
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PsA. In the IVEPSA (Interception in very early PsA) study
psoriatic patients with inflammatory arthralgia without joint
swelling and with concomitant predictors of PsA (i.e. PASI >
6 or scalp psoriasis or nail involvement) were treated with anti-
IL-17 for a disease interception [25••]. Baseline MRI investiga-
tion of the dominant hand revealed at least one inflammatory
lesion in 83% of patients, highlighting synovitis as the most
prevalent (66.7%), followed by tenosynovitis (55.6%). Micro-
erosion and bone proliferation are common in psoriasis subjects
without arthralgia on HR-pQCT [25••]. Therefore, it is no sur-
prise that bone proliferation and erosion were frequently found
in psoriatic inflammatory arthralgia: at least one erosion was




The Imaging of the Synovio-Entheseal Complex
That the enthesis may be closely functionally integrated with
the synovium was first reported in 2007, and this model of
joint inflammation is supported by animal models [26, 27]. In
a TNFΔARE mouse model, chronic and deregulated TNF pro-
duction leading to a spondyloarthropathy phenotype with ar-
thritis and Crohn’s-like ileitis, the onset of inflammation was
seen in the entheses including the collateral ligaments of in-
terphalangeal joints and at the synovio-entheseal complex
(SEC) of the Achilles tendon [7]. The synovium was subse-
quently involved, followed with pannus formation, and finally
involving the entire joint [7] (Fig. 3). Actually, imaging stud-
ies in early PsA confirms this hypothesis highlighting that
PsA, differently from RA, seems not to be a synovial-
centred-disease and presents inflammation affecting a wider
area, including soft tissue and entheses, as well as synovium
[28–30]. In early PsA, the sonographic detection of SEC in-
flammation at metacarpophalangeal joints (i.e. extensor
peritendinitis with or without synovitis) and at proximal inter-
phalangeal joints (i.e. central slip enthesitis with or without
synovitis) were also described [29, 31]. Furthermore, these
sonographic features are useful to differentiate PsA from
RA, both in early and longstanding disease [32].
The role of mechanical strain as a trigger of the inflamma-
tory process within the SEC was recently confirmed [33].
Cambrè et al. found that mechanical strain was an essential
checkpoint for the translation of systemic immune activation
into site-specific joint inflammation in mouse model [33].
This concept was highlighted also in humans: high level of
occupation-related mechanical stress was indeed associated
with increased radiographic peripheral joint damage among
patients with longstanding PsA [34]. Furthermore, Tinazzi
et al. proposed that dactylitis and tenosynovitis could be mod-
ified by early biomechanical alterations in tendon function,
particularly at the pulleys level [35•]. Flexor tendon pulleys
are mini-entheses that anchor the tendons to the bone and are
subjected to very high physical stress. In the study the authors
found that PsA patients had thicker pulleys comparedwith RA
and HCs and this thickness was particularly relevant in
dactylitis [35•]. Globally, this study seems to confirm the role
of anatomical and functional entheses as initial site of inflam-
mation and the mechanical strain as a trigger.
Established Psoriatic Arthritis
The Extraarticular Manifestations and How Those Are Linked
to each Other when Scanned by Imaging
Imaging elucidated the crucial role of entheses in PsA patho-
genesis; the inflammation of these structures is triggered by
functional overload due to overweight or chronic mechanical
micro-trauma. When an inflammatory process became repeat-
ed cells of innate immunity spreads through the enthesis and
Illustration 1. Transition phases from psoriasis to early PsA
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other structures became involved by the inflammatory process
such as joints, bursa, connective tissue, and bone. This is the
case of the link between the inflammation of the nail and the
distal interphalangeal (DIP) joints [36]; MRI studies sug-
gested that the dorsal capsular enthesis of the DIP was the
epicentre of the inflammatory process [37]. Patients with nail
psoriasis are shown to have more extensor tendon enthesitis in
the adjacent extensor tendon insertion on US as well as having
more enthesitis in remote sites [6]. In obese patients the lower
limbs enthesis are chronically stressed and traumatized by the
overload due to overweight; it is therefore easy to observe US
alterations due to chronic enthesitis like bone proliferation and
erosions [17]. According to the hypothesis of obesity as a
promotor of disease activity in PsA, short-term weight loss
treatment was resulted with significant positive effects on dis-
ease activity in joints, entheses, and skin [38]. With imaging,
BMI is found to be linked to entheseal inflammation as well as
new bone formation at the peripheral entheses. The same ef-
fect on new bone formation is also seen for the axial skeleton
with more syndesmophytes and a higher modified Stoke
Ankylosing Spondylitis Spinal Score with increased BMI
[39]. Higher enthesitis scores were also observed in inflam-
matory bowel disease even without symptoms of spondyl
oarthropathy supporting a shared pathogenic mechanism
between IBD and spondyloarthritis (SpA), whereas similar
scores may suggest a general impact of gut inflammation on
the enthesis [40]. Subclinical bowel inflammation was corre-
lated with the severity of spine inflammation [41]. Scarpa
et al. demonstrated that bowel mucosa of patients with PsA
also without bowel symptoms shows microscopic lesions
supporting the pathogenetic link between skin, joints, and
gut in psoriatic patients [42]. Recent research highlighted that
recirculating innate immune cells from the gut to the extra-
intestinal sites as possible responsible for the induction of
chronic inflammatory responses in SpA patients [43]. The
intestine-enthesis axis in PsA is not yet fully elucidated;
whether such as micro-traumatism or a dysbiosis in the intes-
tinal mucosa that alters the intestinal barriers is matter of on-
going studies.
Future Steps and Research Agenda
Imaging Towards Clinical Prevention
Since 80% of PsA patients initially have skin psoriasis, a
marker that can easily be identified with inspection, there is
a potential target for identifying people that has a high risk for
Fig. 1 a–b Dorsal scan of the Achilles tendon. a–b Longitudinal view.
Active enthesitis with loss of the tightly packed echogenic lines (white
asterisks) and concomitant PD signal at bone insertion in a psoriatic
arthralgia patient. c Lateral scan on the elbow. Active enthesitis of the
common extensor tendon enthesis in an early psoriatic arthritis. d Plantar
fascia. Thickening of the plantar fascia in a psoriasis patient. AT, Achilles
tendon; C calcaneus; CET common extensor tendon enthesis; PF plantar
fascia
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developing PsA and treating to prevent the disease. There is a
significant overlap between the treatment of psoriasis and
PsA, and patients present with skin psoriasis first, therefore
effective treatment of psoriasis may stop the progression to
PsA. A retrospective study supported that the incidence of
new symptoms leading to diagnosis of PsA is reduced if pa-
tients are on biological and conventional DMARD therapies
for their skin psoriasis [44•]. In addition, biologic therapies
also seem to have an effect on the disease features as none
of the patients on biologics (given for psoriasis) develop
dactylitis compared to 28.6% of other systemic treatments
and 48.6% of none/local treatment [44•]. A recent prospective
study showed that the interleukin-12 (IL-12)/IL-23 inhibition
reduces the subclinical enthesopathy in psoriasis within
12 weeks which is maintained through week 52 [45••].
These data suggest that treatment of psoriasis may have dis-
ease modifying effects for PsA, and there may be a window of
opportunity to prevent PsA symptoms. This aligns with stud-
ies have shown that psoriasis patients who develop PsA at
follow-up have higher enthesitis scores on the ultrasound at
baseline, years before developing PsA, which supports the
enthesis being the key structure in PsA, and the disease may
be initiated at the level of the entheses [3, 8]. There are ongo-
ing psoriasis cohorts with extensive use of US to visualize the
joints and the enthesis, which hopefully give us more insights
about the pathway from psoriasis to PsA and leading to pre-
vention rather than treatment.
Better Phenotyping Patients in Clinical Practice
and Trials
PsA is a very heterogeneous disease with different “seemingly
unrelated” disease manifestations occurring within the same
presentation. The phenotypes that have been described by
Moll and Wright in 1971 nicely summarizes how patients
can present, namely with axial disease, polyarticular,
oligoarticular arthritis, DIP predominant disease, and arthritis
mutilans, and the determination of the disease phenotypes
have traditionally been based on the clinical assessment
[46]. The number of tender or swollen joints determine wheth-
er it’s a poly vs oligoarticular disease, although this separation
can be artificial as there may be changes in the pattern over
time either due to the disease course or treatment affect [47].
There are no established definitions of axial disease in PsA
or how to screen, which causes major differences across studies
in terms of how often it’s seen. The inflammatory back pain
criteria have been developed in Ankylosing Spondylitis and
have been demonstrated to have a poorer performance in PsA
which may limit their value to be used as screening tools [48,
49]. Supporting this, the percentage of patients axial PsAwithin
Fig. 2 a–d Volar scan of the digit of the hands by ultrasonography. a–b
Longitudinal view. Mild tenosynovitis (white arrowhead) of the flexor
tendon (FT) in a psoriasis patient with arthralgia. c–d Transverse view.
Active tenosynovitis of the flexor tendon in an early psoriatic arthritis.
Dorsal scan of the wrist. e Active tenosynovitis of the extensor digitorum
tendon (EDT) in an established psoriatic arthritis
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PsA cohorts increases if standard imaging is done regardless of
the presentation [50]. This underdiagnosed axial PsA disease
(imaging findings of sacroiliitis and/or syndesmophytes with no
clinical diagnosis of axial disease) has impacts on the patient
outcomes with worse PROs, which cannot be detected if pa-
tients do not have standard screening [51].
The clinical trials use the commonly accepted definitions of
these phenotypes, which have shown significant discrepancies
with imaging modalities. For example, the vast majority of the
clinical trials have only been focusing on the effectiveness of
therapies on polyarticular phenotype in PsA, with few to none
data on the axial disease, clinical enthesitis, or dactylitis as a
primary outcome [52]. The efficacy data on features such as
enthesitis or dactylitis has mostly been exploratory. In a joint-
study from Ottawa, Leeds, and Toronto where US features of
enthesitis were compared with clinical assessment of the same
site, a relationship between clinical and sonographic findings
for large entheses is found to be dependent on the anatomical
site, especially the Achilles tendon and patellar tendon origin,
whereas for some other sites such as the patellar ligament
insertion or plantar fascia, the tenderness on physical exami-
nation did not have any corresponding feature on ultrasound
[53••]. In the absence of a prospective study to compare the
outcomes of patients with or without US-detected inflamma-
tion versus clinical enthesitis, it is not possible to make a
statement on which one is the gold standard. However, the
use of US for entheseal disease, instead of clinical examina-
tion, revealed multiple links between different disease mani-
festations, which could not be captured by using physical
examination only, such as the link between the enthesis and
the nail or the spine [6, 53••, 54]. Therefore, the use of ultra-
sound helps us better phenotype patients not only in clinical
practice but also in clinical trials which may allow us to better
understand the mechanisms causing to those phenotypes and
treat.
Conclusions
Several factors identify those psoriasis patients with the
highest likelihood of progression to PsA, such as nail involve-
ment, severe psoriasis, and obesity; however, various aspects
are still required to clarify the preclinical phases of PsA, from
the definition of PsA risk factors to prediction of PsA devel-
opment [5, 11, 12]. These patients with clinical risk factors of
PsA are often characterized by non-specific symptoms and
Fig. 3 a–b Dorsal scan of the metacarpophalangeal joint by
ultrasonography. a Longitudinal view. Active synovitis in an early
rheumatoid arthritis (synovium-centric disease). b Longitudinal view.
Synovio-entheseal complex (SEC) inflammation (active peritendinitis
of the extensor tendon and mild active synovitis) in an early psoriatic
arthritis (SEC-centric disease). c Dorsal scan of the distal
interphalangeal (DIP) joint by ultrasonography. Longitudinal view.
Synovitis of the DIP joint in an early psoriatic arthritis patient. d Dorsal
scan of the proximal interphalangeal (PIP) joint by ultrasonography.
Longitudinal view. SEC inflammation of the PIP joint (central slip
enthesitis of the extensor tendon and active synovitis). ET extensor
tendon
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few or any objective inflammation [14••, 15••]. In psoriasis
patients with no specific features on clinical examination, im-
aging could play a major role identifying subclinical inflam-
mation and damage that had already occurred. There are small
sample-sized studies with short-term follow-ups that suggest
the prediction of PsA using imaging tools which needs to be
tested in larger series, longer follow-ups, and by linking to
other biomarkers to accurately classify pre-clinical phases of
PsA and to identify which lesions are specifically associated
with higher risk of arthritis development [3, 15••]. In conclu-
sion, in the near future, the correct identification of psoriasis
patients with higher risk for PsA transition could modify the
management of psoriatic disease, leading to treatment strategy
bridging therapy and prevention.
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